RT Journal Article
SR Electronic
T1 Interpretable-by-design Deep Survival Analysis for Disease Progression Modeling
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.11.24310270
DO 10.1101/2024.07.11.24310270
A1 Gervelmeyer, Julius
A1 Müller, Sarah
A1 Djoumessi, Kerol
A1 Merle, David
A1 Clark, Simon J.
A1 Koch, Lisa
A1 Berens, Philipp
YR 2024
UL http://medrxiv.org/content/early/2024/07/11/2024.07.11.24310270.abstract
AB In the elderly, degenerative diseases often develop differently over time for individual patients. For optimal treatment, physicians and patients would like to know how much time is left for them until symptoms reach a certain stage. However, compared to simple disease detection tasks, disease progression modeling has received much less attention. In addition, most existing models are black-box models which provide little insight into the mechanisms driving the prediction. Here, we introduce an interpretable-by-design survival model to predict the progression of age-related macular degeneration (AMD) from fundus images. Our model not only achieves state-of-the-art prediction performance compared to black-box models but also provides a sparse map of local evidence of AMD progression for individual patients. Our evidence map faithfully reflects the decision-making process of the model in contrast to widely used post-hoc saliency methods. Furthermore, we show that the identified regions mostly align with established clinical AMD progression markers. We believe that our method may help to inform treatment decisions and may lead to better insights into imaging biomarkers indicative of disease progression. The project’s code is available at github.com/berenslab/interpretable-deep-survival-analysis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by the Hertie Foundation, the Else Kroener Medical Scientist Kolleg "ClinbrAIn: Artificial Intelligence for Clinical Brain Research", the Bundesministerium fuer Bildung und Forschung through the EYERISK project (BMBF, FKZ 01ZZ2319A) and the German Science Foundation (BE5601/8-1 and the Excellence Cluster 2064 "Machine Learning - New Perspectives for Science", project number 390727645). The authors thank the AREDS participants, and the AREDS Research Group for their valuable contribution to this research. Funding support for AREDS was provided by the National Eye Institute (N01-EY-0-2127).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We used the publicly available AREDS data which can be accessed on request from the dbGaP. The original study states: “Prior to study initiation, the protocol was approved by an independent data and safety monitoring committee and by the institutional review board for each clinical center. Written informed consent was obtained from all participants before enrollment.” Age-Related Eye Disease Study Research Group (2001). A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of ophthalmology (Chicago, Ill. : 1960), 119(10), 1417-1436. https://doi.org/10.1001/archopht.119.10.1417I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData is available through the dbGaP. Code and model weights are available on Github, see the abstract. https://github.com/berenslab/interpretable-deep-survival-analysis https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study\_id=phs000001.v3.p1